Exelixis (EXEL) Announces Initiation of CS-3150 Phase 3 as Selective Mineralocorticoid Receptor Antagonist
Tweet Send to a Friend
Exelixis, Inc. (Nasdaq: EXEL) announced that its partner Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) has initiated a phase 3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
